



- (51) **International Patent Classification:**
C07K 16/40 (2006.01) *A61K 47/68* (2017.01)
- (21) **International Application Number:**
PCT/US2022/073528
- (22) **International Filing Date:**
08 July 2022 (08.07.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/219,977 09 July 2021 (09.07.2021) US
- (71) **Applicant:** **DYNE THERAPEUTICS, INC.** [US/US];
1560 Trapelo Road, Waltham, MA 02451 (US).
- (72) **Inventors:** **DESJARDINS, Cody, A.**; 1560 Trapelo Road,
Waltham, MA 02451 (US). **TANG, Kim**; 1560 Trapelo
Road, Waltham, MA 02451 (US). **MCSWIGGEN, James**;
19395 W. 94th Avenue, Arvada, CO 80007 (US). **SUBRA-
MANIAN, Romesh, R.**; 9 Alan Street, Framingham, MA
01701 (US). **WEEDEN, Timothy**; 1560 Trapelo Road,
Waltham, MA 02451 (US). **QATANANI, Mohammed, T.**;
1560 Trapelo Road, Waltham, MA 02451 (US). **QUINN,
Brendan**; 45 East Newton Street #320, Boston, MA 02118
(US). **NAJIM, John**; 1560 Trapelo Road, Waltham, MA
02451 (US).
- (74) **Agent:** **BUSS, Colin, G.** et al.; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES




FIG. 1

(57) **Abstract:** Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*